Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Phase 1 Clinical Trial in Patients With Advanced Malignancies

This study has been completed.
Information provided by (Responsible Party):
Triphase Research and Development I Corporation Identifier:
First received: February 26, 2008
Last updated: August 11, 2014
Last verified: August 2014
This is a Phase 1 clinical trial examining the safety, pharmacokinetics and pharmacodynamics of escalating doses of the proteasome inhibitor NPI-0052 in patients with advanced malignancies including solid tumors, lymphomas, leukemias and multiple myeloma. By inhibiting proteasomes NPI-0052 prevents the breakdown of proteins involved in signal transduction, which blocks growth and survival in cancer cells.

Condition Intervention Phase
Advanced Malignancies
Drug: NPI-0052
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

Resource links provided by NLM:

Further study details as provided by Triphase Research and Development I Corporation:

Primary Outcome Measures:
  • To determine Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of NPI 0052 when administered via IV injection on Days 1, 8, 15 during a four week cycle for patients with advanced malignancies [ Time Frame: Continuous ]

Secondary Outcome Measures:
  • To evaluate the pharmacokinetics, toxicity profile, biological activity, pharmacodynamics and anti-tumor activity of NPI-0052 in patients with these malignancies. [ Time Frame: Continuous ]

Enrollment: 86
Study Start Date: July 2007
Study Completion Date: April 2013
Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Advan. malignancies
IV injection of NPI-0052
Drug: NPI-0052
IV injection
Other Names:
  • Marizomib
  • proteasome inhibitor
Experimental: multiple myeloma
IV injection of NPI-0052
Drug: NPI-0052
IV injection
Other Names:
  • Marizomib
  • proteasome inhibitor


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Karnofsky Performance Status (KPS) > 70%.
  • Histologically-confirmed advanced malignancy for which a standard, approved therapy is not available.
  • Adequate renal, liver, pancreatic and hematologic function
  • Signed informed consent (sample IC form is provided in Appendix A).

Exclusion Criteria

  • Administration of chemotherapy, biological, immunotherapy or investigational agent (therapeutic or diagnostic) within 28 days
  • Patients that require G-CSF and/or platelet support during screening and are likely to require G-CSF and/or platelet support for the duration of the clinical trial.
  • Patients with ongoing coagulopathies and/or taking anticoagulants
  • Patients receiving intrathecal therapy.
  • Known brain metastases.
  • Pre-existing adrenal insufficiency; concomitant therapy with replacement corticosteroids. Pre-existing acute or chronic pancreatitis.
  • Significant cardiac disease.
  • Pregnant or breast-feeding women.
  • Concurrent, active secondary malignancy for which the patient is receiving therapy. (Lymphoma patients with a diagnosis of a potentially hormone-sensitive tumor who are without evidence of disease for this second malignancy may continue to receive hormonal therapy).
  • Patients with proteinuria Grade 2 or greater
  • Active uncontrolled bacterial or fungal infection requiring systemic therapy; infection requiring parenteral antibiotics.
  • Patients who are known to be HIV positive or have active Hepatitis A, B, or C infection.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00629473

Australia, Queensland
Mater Adult Hospital
South Brisbane, Queensland, Australia, 4101
Australia, South Australia
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia, 5001
Australia, Victoria
Peter MacCallum Cancen Center
Melbourne, Victoria, Australia, 3002
The Alfred Hospital
Melbourne, Victoria, Australia, 3168
Border Medical Oncology
Wodonga, Victoria, Australia, 3690
Australia, Western Australia
Sir Charles Gairdner Hospital and University of Western Australia
Nedlands, Western Australia, Australia, 6009
Royal Perth Hospital
Perth, Western Australia, Australia, 6001
Sponsors and Collaborators
Triphase Research and Development I Corporation
Study Director: Steven D Reich, MD Triphase Research and Development I Corp
  More Information

Responsible Party: Triphase Research and Development I Corporation Identifier: NCT00629473     History of Changes
Other Study ID Numbers: NPI 0052-102
Study First Received: February 26, 2008
Last Updated: August 11, 2014

Keywords provided by Triphase Research and Development I Corporation:
multiple myeloma
leukemias (inc. CLL)
cutaneous lymphoma
marginal zone lymphoma
advanced malignancies without standard treatment options

Additional relevant MeSH terms:
Proteasome Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017